Showing results (131-140 of 148) with videos related to
Sort By:
Pageof 15
Arthritis Research & Therapy|August 30, 2019
Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritisKi-Nam Gu, So-Young Bang, Hye-Soon Lee, et al.Rheumatology (Oxford, England)|June 12, 2019
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trialSeung Cheol Shim, Ljubinka Božić-Majstorović, Alfredo Berrocal Kasay, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 15, 2017
Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled TrialDae Hyun Yoo, Chang-Hee Suh, Seung Cheol Shim, et al.Journal of Korean Medical Science|December 26, 2018
Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in KoreaJason Jungsik Song, Yeong Wook Song, Sang Cheol Bae, et al.Scientific Reports|June 9, 2016
Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritisKwangwoo Kim, So-Young Bang, Katsunori Ikari, et al.Modern Rheumatology|May 5, 2016
What factors affect discordance between physicians and patients in the global assessment of disease activity in rheumatoid arthritis?Soo-Kyung Cho, Yoon-Kyoung Sung, Chan-Bum Choi, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 6, 2019
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III TrialChang-Hee Suh, Dae Hyun Yoo, Alfredo Berrocal Kasay, et al.Annals of the Rheumatic Diseases|July 30, 2020
Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritisYoung-Chang Kwon, Jiwoo Lim, So-Young Bang, et al.Mabs|July 17, 2018
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trialWon Park, Ljubinka Božić-Majstorović, Dragana Milakovic, et al.Journal of Korean Medical Science|November 9, 2016
Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid ArthritisYoon Kyoung Sung, Soo Kyung Cho, Dam Kim, et al.Pageof 15